Karyopharm Therapeutics (KPTI) Tops Q2 EPS by 1c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.64), $0.01 better than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance
• HP Inc. (HPQ) Tops Q3 EPS by 17c, Beats on Revenue; Offers FY Guidance
• Bath & Body Works, Inc. (BBWI) Tops Q2 EPS by 38c, Offers FY27 EPS Guidance